Inclusion Criteria:  All groups  Age and gender matching  Age between 18 and 40  Enrolled in a social security plan  Normal or corrected-to-normal visual acuity verified by Monoyer test  In women of childbearing age: negative urine pregnancy test at the inclusion visit  Person who has received and understood prior information about the study  Person who has given free and informed written consent prior to any participation in the study  Healthy control group (HC; n=30)  Met "all groups" criteria  No current disorders as assessed by the MINI global assessment  No lifetime (hypo)manic episodes or psychotic disorders and current  No current or past disorders by CAARMS assessment  No current disorders according to ICD-10 criteria  No positive family history (parents/first degree) for affective affective, non-affective psychoses or major affective disorders  No regular use (more than 3 psychotropic medications: benzodiazepines, hypnotics,antidepressants, antipsychotics or mood regulators or psychostimulants) during the past last 12 months  High clinical risk group for psychosis (CHRP; n=30)  Met "all groups" criteria, Assessment at CAARMS:  Attenuated positive symptoms (APS) OR Brief Intermittent Psychotic Symptoms (BIPS) OR Attenuated psychosis of sub-laminar frequency OR sub-laminar attenuated psychosis  Antipsychotic treatment with a cumulative dose of equivalent chlorpromazine <2500mg lifetime (1)  First Episode Psychosis (FEP; n=30)  All-group criteria met CAARMS assessment: Psychosis/antipsychotic treatment threshold treatment threshold achieved at CAARMS  Antipsychotic treatment with a cumulative dose of equivalent chlorpromazine <2500mg lifetime (1)  Exclusion Criteria (all groups):  Impairment of the subject that makes it difficult or impossible to participate in the or comprehension of the information provided to him/her  Dyslexia  Substance use disorder according to CIM-10  Neurological history including progressive neurological pathology  Progressive retinal disease  Chronic glaucoma  Ophthalmologic pathology affecting visual acuity  Current ocular infection  Major under guardianship, curatorship or safeguard of justice  Pregnant or breastfeeding women  Persons in a life-threatening emergency situation  Result of the preliminary medical examination incompatible with the research  Patient presenting a suicidal risk.  Criteria incompatible with the use of the Retinaute:  Allergy to silver Known or suspected allergy to any of the following components:  polyamide, polyester, elastane, latex, rubber, silicone, or any synthetic material as well as to cotton in case the device is used without the device is used without a protective head covering  Sensory disorders making the patient insensitive to pain on the skin. Behavioral problems making the patient extremely agitation or aggression. Mental disorders incompatible with the use of the device. Seizure disorder. Open wound in an area covered or wrapped by the device. User at high risk of contagion. Wearing an implantable medical device (e.g. pacemaker) Pregnant women, women in labor or nursing mothers. Allergy or skin sensitivity to one of the components of the cream Elefix or equivalent on the market: coconut oil, egg oil, propylene glycol egg oil, propylene glycol, glycerin, lanolin... Allergy or skin sensitivity to one of the components of the cream NuPrep or market equivalent  Participation in another interventional study (exclusion period included)